A new colorectal cancer drug has shown unexpected results with a 100% success rate in clinical trials, according to a new study.
Thanks to dostarlimab, a drug containing molecules that act as antibodies, given to 18 patients in remission one year following testing the drug, the researchers found no trace of cancer in their bodies.
The study published in the New England Journal of Medicine on Tuesday finds that patients who completed treatment with dostarlimab had a complete clinical response without reporting a tumor on magnetic resonance imaging (MRI).
The team of researchers led by Dr. Luis A. Diaz Jr. from Memorial Sloan Kettering Cancer Center in New York observed that the patients were not subjected to a session of chemotherapy or underwent surgery during the follow-up period. .
The study is considered a world first, in that the trial of the new drug resulted in complete remission and almost no adverse effects in all patients who participated in the study.
The researchers believe, however, that a longer follow-up (25 months) is necessary to assess the response to the administration of dostarlimab, which has led to unexpected results so far, according to Dr. Diaz.
